Teva Raises 2026 Outlook After 33% Growth in Key Brands
Teva said its neuroscience portfolio is expanding through the Weltruza launch and the addition of BXCL-501.
Teva said its neuroscience portfolio is expanding through the Weltruza launch and the addition of BXCL-501.